UA90659C2 - Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ - Google Patents

Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ

Info

Publication number
UA90659C2
UA90659C2 UAA200602710A UAA200602710A UA90659C2 UA 90659 C2 UA90659 C2 UA 90659C2 UA A200602710 A UAA200602710 A UA A200602710A UA A200602710 A UAA200602710 A UA A200602710A UA 90659 C2 UA90659 C2 UA 90659C2
Authority
UA
Ukraine
Prior art keywords
tyrosine kinase
kinase inhibitors
receptor tyrosine
quinazoline analogs
analogs
Prior art date
Application number
UAA200602710A
Other languages
English (en)
Ukrainian (uk)
Inventor
Эли Уоллейс
Георгий Топалов
Джозеф ЛИССИКАТОС
Александр Бакмельтер
Цян Чжао
Original Assignee
Аррей Байофарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аррей Байофарма Инк. filed Critical Аррей Байофарма Инк.
Publication of UA90659C2 publication Critical patent/UA90659C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Данное изобретение касается аналогов хиназолина Формулы И:,где А прикреплено к по меньшей мере одному из углеродов в положении 5, 6, 7 или 8 бициклического кольца, и кольцо замещено как минимум двумя независимыми группами R.Изобретение также включает способы применения соединений Формулы И как ингибиторов рецепторной тирозинкиназы типа И и для лечения гиперпролиферативных заболеваний, таких как рак.
UAA200602710A 2003-08-14 2004-08-10 Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ UA90659C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
UA90659C2 true UA90659C2 (ru) 2010-05-25

Family

ID=34549763

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200602710A UA90659C2 (ru) 2003-08-14 2004-08-10 Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ

Country Status (6)

Country Link
US (7) US7501427B2 (ru)
EP (1) EP2377539A1 (ru)
CN (1) CN1852714A (ru)
SI (1) SI1660090T1 (ru)
UA (1) UA90659C2 (ru)
ZA (1) ZA200601333B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN103664802B (zh) * 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
US7501247B2 (en) * 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
US8648087B2 (en) 2005-11-15 2014-02-11 Array Biopharma, Inc. N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
CA2720987A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Dosages and methods for the treatment of cancer
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
PL2496567T3 (pl) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Nowe benzopiranowe modulatory kinazy
SG194718A1 (en) 2011-05-04 2013-12-30 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
JP5944514B2 (ja) 2011-10-14 2016-07-05 アレイ バイオファーマ、インコーポレイテッド 固体分散体
JP2014530243A (ja) 2011-10-14 2014-11-17 アレイ バイオファーマ、インコーポレイテッド Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物
ES2647416T3 (es) 2012-07-04 2017-12-21 Rhizen Pharmaceuticals S.A. Inhibidores de PI3K delta selectivos

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) * 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5204348A (en) 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
JPH0779706B2 (ja) * 1990-03-22 1995-08-30 田辺製薬株式会社 ２―クロロ―３―ヒドロキシ―３―フエニルプロピオン酸エステル類の製法
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (ru) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EP0880508B1 (en) * 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ332119A (en) * 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
CN1104139C (zh) 1996-10-02 2003-03-26 索尼公司 电视接收机、设置接收频道的方法和图像显示方法
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
PL340589A1 (en) 1997-11-11 2001-02-12 Pfizer Prod Inc Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
IL143089A0 (en) 1998-11-19 2002-04-21 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US6189091B1 (en) * 1998-12-02 2001-02-13 Ip First, L.L.C. Apparatus and method for speculatively updating global history and restoring same on branch misprediction detection
NZ513433A (en) 1999-01-13 2003-05-30 Warner Lambert Co Benzoheterocycles, their use as MEK inhibitors and use in treating proliferative diseases such as cancer
AU763242B2 (en) * 1999-09-21 2003-07-17 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
PL201790B1 (pl) * 2000-02-17 2009-05-29 Bristol Myers Squibb Co Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna
CA2411084A1 (en) * 2000-06-06 2001-12-13 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
DE60108754T2 (de) * 2000-06-22 2005-06-23 Pfizer Products Inc., Groton Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
CZ299561B6 (cs) 2000-06-30 2008-09-03 Glaxo Group Limited Chinazolinaminový derivát a farmaceutický prostredek
WO2003015778A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002361577A1 (en) 2001-10-30 2003-05-12 Merck And Co., Inc. Tyrosine kinase inhibitors
US20050043336A1 (en) * 2001-11-03 2005-02-24 Hennequin Laurent Francois Andre Quinazoline derivatives as antitumor agents
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP2006515871A (ja) * 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
WO2004106308A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN103664802B (zh) 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
JP2007502807A (ja) * 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Ｅｒｂｂ２抗がん剤の投与スケジュール
CA2544863A1 (en) * 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US8648087B2 (en) 2005-11-15 2014-02-11 Array Biopharma, Inc. N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
US20190161500A1 (en) 2019-05-30
US20210284656A9 (en) 2021-09-16
US7585975B2 (en) 2009-09-08
US20170260202A1 (en) 2017-09-14
CN1852714A (zh) 2006-10-25
US9676791B2 (en) 2017-06-13
US20210269455A1 (en) 2021-09-02
US20130245256A1 (en) 2013-09-19
ZA200601333B (en) 2007-05-30
US11174273B2 (en) 2021-11-16
US7501427B2 (en) 2009-03-10
US20090270621A1 (en) 2009-10-29
US20050101616A1 (en) 2005-05-12
US20080194558A1 (en) 2008-08-14
EP2377539A1 (en) 2011-10-19
US7777032B2 (en) 2010-08-17
US10221194B2 (en) 2019-03-05
SI1660090T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
RS20050042A (en) Novel inhibitors of kinases
RS20050363A (en) Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
SE0303180D0 (sv) Novel compounds
RS20050441A (en) C-6 modified indazolylpyrroltriazines
WO2005002626A3 (en) Therapeutic phosphonate compounds
TW200614996A (en) Antiviral compounds
UA91688C2 (en) Antiviral compounds
WO2004096286A3 (en) Antiviral phosphonate analogs
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
GB0112348D0 (en) Compounds
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
HK1118534A1 (en) Thieno-pyrimidine compounds having fungicidal activity
EP1773791A4 (en) PYRROLOTRIAZINVERBINDUNGEN
WO2004096233A3 (en) Nucleoside phosphonate conjugates
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
MXPA05011294A (es) Compuestos de fosfonato anti-inflamatorios.
MXPA05011289A (es) Compuestos de fosfato que tienen actividad inmunomoduladora.
EA200600416A1 (ru) Производные циклопропила в качестве антагонистов рецептора nk3